FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/04/066390 [Registered on: 26/04/2024] Trial Registered Prospectively
Last Modified On: 26/04/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A study to compare injectable iron with oral iron tablets for correction of anemia among patients planned for gynecological surgeries 
Scientific Title of Study   Preoperative intravenous ferric carboxymaltose versus oral ferrous ascorbate for anaemic patients undergoing elective gynecological surgery – A Randomised controlled trial Pilot Study 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Sayanti Paul 
Designation  Assistant Professor 
Affiliation  AIIMS, Kalyani 
Address  Department of Obstetrics and Gynecology (2nd floor OPD), AIIMS Hospital

Nadia
WEST BENGAL
741245
India 
Phone  09836799167  
Fax    
Email  ichchedana.sayanti@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Sayanti Paul 
Designation  Assistant Professor 
Affiliation  AIIMS, Kalyani 
Address  Department of Obstetrics and Gynecology (2nd floor OPD), AIIMS Hospital campus


WEST BENGAL
741245
India 
Phone  09836799167  
Fax    
Email  ichchedana.sayanti@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Sayanti Paul 
Designation  Assistant Professor 
Affiliation  AIIMS, Kalyani 
Address  Department of Obstetrics and Gynecology (2nd floor OPD), AIIMS Hospital campus


WEST BENGAL
741245
India 
Phone  09836799167  
Fax    
Email  ichchedana.sayanti@gmail.com  
 
Source of Monetary or Material Support  
Intramural funding, All India Institute of Medical Sciences NH34 connector, Saguna, Basantapur Dist - Nadia, PIN 741245, State - West Bengal 
 
Primary Sponsor  
Name  AIIMS, Kalyani 
Address  NH34 connector, Basantapur, Kalyani 741245 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Sayanti Paul  All India Institute of Medical Sciences  2nd Floor OPD, Department of Obstetrics and Gynecology, NH34 connector, Saguna, Basantapur
Nadia
WEST BENGAL 
9836799167

ichchedana.sayanti@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee AIIMS Kalyani  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: D509||Iron deficiency anemia, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Injection ferric carboxymaltose  Dosing - First group will receive preoperative injection FCM 15mg/kg maximum 1000 mg 4 weeks prior to surgery. FCM will be diluted in 100-200 ml saline and infused over 20-30 mins. Patients will be kept under observation for 1 hour post infusion in gynecology day care. There is provision of second dose of 500 mg FCM injection if preoperative hemoglobin level fails to rise above 10gm/dl 4 weeks after first dose. Cumulative dose of FCM should not be more than 1500 mg/dl for a single patient. Surgery will be done at least 2 weeks after the second dose of injection FCM if received.  
Comparator Agent  Oral Ferrous Ascorbate tablet  Dosing - Oral tablet Ferrous Ascorbate 100 mg twice daily 1 hour after food for 4 weeks. There is provision of giving another 4 weeks of ferrous ascorbate if preoperative hemoglobin fails to rise upto 10 gm/dl 4 weeks after starting oral treatment.  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  70.00 Year(s)
Gender  Female 
Details  1.Patients with Hemoglobin concentration between 8-12gm/dl and low serum ferritin transferrin saturation or raised TIBC who have been scheduled for elective major gynecological surgeries
2.Patients who are willing to participate and give consent
 
 
ExclusionCriteria 
Details  1.Patients who are pregnant
2.Patients suffering from other forms of anemia except iron deficiency
3.Patients having known hypersensitivity to FCM
4.Patients suffering from Iron storage disorders
5.Patient having serious medical condition or uncontrolled systemic disorders that would prohibit her from participating in the investigation
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1.Change in hemoglobin (gm/dl) from baseline to day of surgery
2.Change in serum ferritin (ng/ml) from baseline to 1 month after surgery
 
4 weeks before operation
Day of surgery
1 month after surgery
 
 
Secondary Outcome  
Outcome  TimePoints 
1.Proportion of patients requiring perioperative red blood cell transfusion
2.Postoperative complications within 30 days of surgery (e.g. surgical site infections, venous thromboembolism, cardiovascular events, respiratory failure, acute kidney injury, sepsis, death)
3.Length of postoperative hospital stay (days)
4.Changes in the Quality-of-life score on WHOQOL-BREF questionnaire at recruitment and 1 month after surgery
5.Number and severity of adverse reactions related to study medications during treatment period.
6.Measurement: Incidence and severity of side effects related to oral iron or FCM, such as gastrointestinal disturbances, allergic reactions and changes in serum vitamin D and phosphorus level.
7.Change in hemoglobin from baseline to day 2 post-op
8.Number of patients screened, eligible, enrolled, completed - to assess recruitment and retention rates
 
4 weeks before operation
Day of surgery
Post operative day 2
1 month after surgery
 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/06/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Background and Rationale- Preoperative anemia is an independent risk factor for postoperative morbidity, mortality, and blood transfusions. There is very high prevalence of iron deficiency anemia in India and women of reproductive age group suffering from gynecological diseases are more prone to develop the same. Rapid and timely correction of iron deficiency anemia before elective gynecological surgery may improve postoperative recovery and may have long term impact on quality of life. However previous studies have shown mixed results and well-designed randomized controlled trials on the same study population from India are lacking. Hence, we propose to perform a randomized controlled trial pilot study to compare Ferric carboxymaltose (FCM) versus oral iron for postoperative recovery among anemic women undergoing elective gynecological surgeries.

Objectives –

a.     Primary Objective

                                               i.     To compare change of pre and postoperative blood parameters (hemoglobin and ferritin) between two groups.

b.     Secondary objectives

                                               i.     To compare postoperative morbidity including blood transfusion requirements between two groups

                                             ii.     Comparison of treatment related adverse effects between two groups.

                                           iii.     Comparison of changes in the quality of life score (WHOQOL- BREF) between two groups

                                            iv.     To assess feasibility of study design in terms of recruitment rates, implementation barriers and attrition rate

Study Methods- It will be an open level parallel group randomized controlled trial including 50 patients in each group and study will be conducted over 1 year in the department of Obstetrics and Gynecology, AIIMS Kalyani. Willing patients with hemoglobin 8-12gm/dl planned for elective gynecological surgeries will be included in this study after confirming iron deficiency anemia and ruling out the exclusion criteria. All recruited patients will be randomly allocated to ferric carboxymaltose or oral iron group. Patients in FCM group will receive injection FCM 15mg/kg in gynecology day care 4 weeks prior to elective surgery and patients in oral iron group will receive oral ferrous ascorbate 100 mg twice daily till surgery for 4 weeks. Follow-up will be done till 1 month after surgery.

Study will be registered under CTRI and any serious drug related serious adverse events will be notified to the appropriate authority as per Institute protocol.

 

Study outcomes –

a.     Primary Outcomes:

                                               i.     Change in hemoglobin (gm/dl) from baseline to day of surgery and 1 month after surgery

                                             ii.     Change in serum ferritin (ng/ml) from baseline to 1 month after surgery

b.     Secondary Outcomes:

                                               i.     Proportion of patients requiring perioperative red blood cell transfusion

                                             ii.     Postoperative complications within 30 days of surgery (e.g. surgical site infections, venous thromboembolism, cardiovascular events, respiratory failure, acute kidney injury, sepsis, death)

                                           iii.     Length of postoperative hospital stay (days)

                                            iv.     Changes in the Quality-of-life score on WHOQOL-BREF questionnaire at recruitment and 1 month after surgery

                                             v.     Number and severity of adverse reactions related to study medications during treatment period.

                                            vi.     Measurement: Incidence and severity of side effects related to oral iron or FCM, such as gastrointestinal disturbances, allergic reactions and changes in serum vitamin D and phosphorus level.

                                          vii.     Number of patients screened, eligible, enrolled, completed - to assess recruitment and retention rates


 
Close